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The “blue” side of glutamatergic neurotransmission:  
NMDA receptor antagonists as possible novel therapeutics  
for major depression
In spite of the wide-ranging, continuously expanding arsenal of antidepressants and inten-
sive research on depression, the treatment of severe, recurrent mood disorders as well as 
antidepressant-resistant refractory mood disturbances has not yet entirely been solved. In this 
article we attempt to review some data from the growing body of evidence that underlie the 
presumed implication of the glutamatergic neurotransmission in severe mood disorders and 
thereby some strategies allowing reinstatement of the normal functioning of the glutamatergic 
system, particularly through N-methyl-d-aspartate (NMDA) receptors. Thus, here we focus on 
one of the most promising ones, the NMDA receptor-modulating agents including competitive 
NMDA antagonists, glycine site partial antagonists and channel site antagonists: high- and 
low-affinity non-competitive NMDA receptor blockers. The glutamate-modulating therapies 
that specifically affect this system, above all low-affinity non-competitive NMDA receptor 
antagonists such as amantadine and its derivative memantine which are clinically well toler-
ated and currently used in other indications hold considerable promise for the development 
of new, improved antidepressants to treat severe, recurrent and refractory mood disorders.    
(Neuropsychopharmacol Hung 2012; 14(1): 29-40; doi: 10.5706/nph201203003)
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IntroductIon: clInIcal features and 
avaIlable therapeutIcs In depressIon
Mood disorders, including major depressive disorder 
(MDD) and bipolar disorder (BPD) are overwhelming, 
often life-threatening psychiatric diseases that affect 
millions of people worldwide. Patients afflicted with 
recurrent mood disturbances experience substantial 
suffering with functional impairment leading to social 
and occupational disability. For many patients, the 
long-term outcome is unfavourable, with relapses, 
incomplete inter-episode syndromal and functional 
recovery, persistent residual symptoms, progressive 
wane in psychosocial functioning (Tohen et al., 2000; 
Fagiolini et al., 2005), and potentially higher risk for 
suicide. Untreated or ineffectively treated mood disor-
ders and markedly depression are considered, in fact, 
as principal clinical substrates of suicidality (Angst 
et al., 1999; Rihmer & Kiss, 2002; Rihmer & Akiskal, 
2006, Rihmer et al., 2008).  
Recurrent mood disorders, previously regarded as 
good prognosis conditions, can therefore be chronic, 
progressive illnesses that have as profound an impact 
on overall functioning with temporary and/or perma-
nent disability as other serious, chronic medical illness-
es, like cerebrovascular disease, HIV/AIDS or chronic 
obstructive pulmonary disease. Indeed, major depres-
sion is ranked as one of the ten leading conditions 
for global diseases burden considering the number 
of disability adjusted life years (Lopez et al., 2006). 
Growing evidence on the underlying etiology and 
neurobiology indicates that severe mood disorders are 
associated with impairments of structural and func-
tional plasticity in specific brain areas. Neuroplastic 
events, impairment of neuroplasticity and cellular 
resilience are likely involved in the pathophysiology 
of mood disturbances, corresponding to reduced cor-
tical volume related to reductions in neuronal and 
glial size and/or density, predominantly in prefrontal 
cortical regions, amygdala, hippocampal areas and 
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basal ganglia. Thus, recent evidence and appreciation 
reshape views about severe mood disorders which are 
contemporarily conceptualized as complex interac-
tions of various susceptibility genes and environmen-
tal factors such as severe and/or prolonged stress, 
implicating also a constellation of cognitive, motoric, 
endocrine and vegetative dysfunctions, which finally 
lead to the phenotypic expression of severe and often 
progressive mood disturbances (Manji et al., 2003).   
In spite of the wide range of pharmacotherapies 
currently available for the treatment of depression, 
a relatively small portion of the patients who receive 
adequate antidepressant therapy will achieve complete 
recovery. A recent effectiveness study revealed that 
only about 30% of patients with nonpsychotic MDD 
achieved full remission with citalopram medication 
after appropriate duration of treatment (Trivedi et al., 
2006). Another study focusing on the outcomes of de-
pressed patients who have not responded adequately 
to previous, successive treatment trials found low 
remission rates (<20%) with a third antidepressant 
monotherapy and the response rates were also below 
20% (Fava et al., 2006). Furthermore, there is mount-
ing clinical and literature evidence that approximately 
10% to 20% of adequately treated patients will remain 
persistently depressed in spite of multiple treatment 
steps and trials. Treatment-resistance and particu-
larly antidepressant-resistance in major depression is 
still regarded, thereby, as a serious clinical challenge. 
Nonetheless, it is indispensable to emphasise that one 
of the causes of antidepressant-resistance in major 
depression can be the unrecognized bipolar character 
of the disorder, including patients with “prebipolar” 
major depression (O’Donovan et al., 2008) as well as 
MDD patients with subthreshold bipolarity (Keck et 
al., 2008; Angst et al., 2010). Antidepressant mono-
therapy in undetected bipolar or bipolar spectrum 
depression can result in markedly higher treatment-
resistance compared to “pure” unipolar major depres-
sion (Ghaemi et al., 2004; Woo et al., 2008). Loss of 
response or inadequate response to usual and often 
repeated trials of antidepressants in major depression 
may indicate, therefore, in special clinical conditions, 
the underlying bipolar diathesis (Rihmer & Gonda, 
2011).        
It is important to underline that the available, con-
tinuously expanding arsenal of antidepressants still 
have limitations regarding efficacy, tolerability and 
side effects. The advantages of antidepressant drugs 
over another(s) are generally based upon side-effect 
profiles, but there are no substantial differences and 
advances in their efficacy and the rapidness of the 
antidepressant effect (Sen & Sanacora, 2008). Thus, in 
spite of the availability of newer antidepressants with 
ameliorated adverse-effect facets, these medications 
are widely similar therapies in as much as they have 
considerable latency in onset of action and they have 
essentially the same mechanism of action. Following 
the identification of TCAs and monoamine oxidase 
inhibitors (MAOIs), the majority of antidepressants, 
among them the widely used SSRIs and SNRIs, act pri-
marily through monoaminergic mechanisms, modu-
lating principally the serotonergic and noradrenergic 
systems. Accordingly, neurobiological and clinical 
studies of mood disorders over the past decade have 
excessively focused on the monoaminergic systems, 
attempting to elucidate the underlying pathophysi-
ology and to reveal the specific alterations in these 
neurotransmitter systems. The monoaminergic path-
ways abundantly project to the striatal, limbic and pre-
frontal cortical structures and are widely distributed 
throughout these neuronal circuits which are thought 
to be responsible for the behavioural and visceral 
aspects of mood disorders (Drevets, 2001; Nestler et 
al., 2002).  Depressive symptom clusters are consid-
ered, thereby, to be associated with different neuro-
transmitter systems and neuroanatomic structures, 
this approach allowing a differential examination 
of the major symptoms of depression (Faludi et al., 
2010). Although dysfunction in the monoaminergic 
neurotransmitter systems is likely involved in the 
pathophysiology of mood disorders and it probably 
mediates certain aspects of the disorder, there has 
been a growing appreciation that it might represent 
the sequels of other, more pivotal abnormalities. The 
majority of antidepressants initially act by enhancing 
the intrasynaptic levels of biogenic amines via inhi-
biting monoamine reuptake and/or metabolism but 
the amelioration of core depressive symptoms is ob-
served only after continuous, chronic administration, 
suggesting that alterations in downstream cascades, 
enduring adaptive changes in neuronal processes are 
finally responsible for their therapeutic effects. This 
timing, the lag period of onset of action of existing 
antidepressant agents supports the assumption that 
dysfunction within the monoaminergic systems is 
subsequent to other, more incipient abnormalities 
(Payne et al., 2002). The delayed adaptive and thera-
peutic effects of classical amine-modulating antide-
pressants are supposed to be mediated by intracellular 
signalling pathways as well as the glutamatergic sys-
tem (Skolnick et al., 2001; Manji et al., 2003). Adap-
tive processes in the adult central nervous system in 
response to external and internal stimuli converging 
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with neurotrophic signalling cascades, outlined as 
neuroplasticity include alterations in the cytoskeletal 
network and consequently, in actin-based dendritic 
spine morphology, maintenance of spine architecture, 
synaptic structure and function, synaptic remodelling, 
neurite outgrow, synapto- and neurogenesis (Matus, 
2000; Carlisle & Kennedy, 2005; Tada & Sheng, 2006; 
Kojima & Shirao, 2007). Several lines of evidence 
articulate the unequivocal role of the glutamatergic 
sytem in neuroplastic events (Mattson, 2008), as well 
as the relevance of neuroplasticity in mood disorders 
(Manji et al., 2003). The role of the glutamatergic 
neurotransmitter system, therefore, should be consid-
ered in the biology of mood disorders. Accordingly, 
increasing preclinical and clinical data suggest that 
the glutamatergic system is involved in the patho-
physiology of mood disorders and mounting evidence 
appreciate the role of glutamate in the mechanism of 
antidepressant action (Maeng & Zarate, 2007).
overvIew of the glutamatergIc system 
Glutamate is the most abundant excitatory neuro-
transmitter in the mammalian central nervous system, 
and glutamate receptors, as the principal mediators 
of excitatory synaptic transmission, are prominently 
implicated in several, normal and pathological brain 
functions. Glutamate has been shown to exert a cru-
cial role in the developing and the mature nervous 
system since it regulates neurogenesis, axonal sprout-
ing, synaptogenesis, programmed cell death (apop-
tosis) and neuron survival. It is also well-established 
that glutamate can be excitotoxic under a variety of 
experimental and pathological conditions, leading 
to rapid or protracted neuronal cell death. Excessive 
and prolonged exposition to glutamate, especially 
when energy availability is impaired and oxidative 
stress increases, induces distinct cellular phenomena 
of excitotoxicity, which has exhaustively been proved 
to be involved in epileptic seizure-induced neuronal 
death, stroke, traumatic brain injury, as well as in 
certain neurodegenerative disorders such as Hunting-
ton’s disease and amyotrophic lateral sclerosis (ALS) 
(overviewed in Mattson, 2008). A precise regulation of 
the glutamatergic excitation is thereby indispensable 
to assure neuroplasticity and to avoid the occurrence 
of excitotoxicity. Glutamate acts via cell surface re-
ceptors which are linked to Ca2+ influx and elevation 
of intracellular Ca2+ levels, resulting in kinase- and 
protease-mediated rapid, as well as transcription-
dependent delayed adaptive responses that modify 
neuronal function and morphology. Glutamate exerts 
prompt changes in dendritic membrane excitability, 
cytoskeletal dynamics and architecture, whereas 
delayed responses involve transcriptional changes 
of genes contributing to neuroplastic events. Local, 
rapid changes in dendritic function and structure, 
rapid dendritic spine reorganization have recently 
been shown to be essential for short- and long-term 
plasticity and to be related to cognition and memory 
(Kasai et al., 2010). Glutamate also elicits delayed 
transcriptional changes, including production of 
neurotrophic factors, which, on the other hand, in-
teract with glutamate to regulate activity-dependent 
neuroplasticity (Mattson, 2008). 
Glutamate is the major excitatory neurotransmit-
ter in the hippocampal formation: the main gluta-
matergic afferents to the hippocampus are repre-
sented by the perforant pathway originating in the 
entorhinal cortex and terminating in dentate gyrus. 
The dentate gyrus is the target for the majority of 
the glutamatergic entorhinal afferents by providing 
sensory information of multiple modalities about 
the external world (Freund & Buzsáki, 1996). The 
dentate gyrus is considered to be the first element in 
the hippocampal synaptic chain that additionally in-
cludes synapses between mossy fibers and CA1-CA3 
areas, and synapses of the Schaffer collaterals with 
CA1 pyramidal cells/subiculum. There is extensive 
data that the neurotransmitter for members of this 
hippocampal circuit is glutamate. Glutamate, as the 
principal excitatory neurotransmitter in the hippo- 
campus, has a key role in long-term potentiation 
(LTP), memory and learning, synaptic plasticity, but 
also in excitotoxic and neurodegenerative processes. 
LTP, the cellular basis of rapid formation of new 
memories, is a property of certain synapses, including 
those of the mossy fibers and the Schaffer collaterals 
of the hippocampus; long-term alteration of synaptic 
transmission occurs at excitatory synapses, which is 
thought to be the basis of specific associative memory. 
Both LTP and long-term depression (LTD) depend on 
activity-dependent Ca2+ increase in the postsynaptic 
neurons, and enhancement or decrease in the LTP/
LTD phenomenon is the cellular substratum of syn-
aptic plasticity. Synaptic plasticity depends, therefore, 
on the increase of intracellular Ca2+ level in the post-
synaptic neuron, which occurs principally through 
the glutamate receptors of the N-methyl-d-aspartate 
(NMDA) subtype and the voltage-dependent Ca2+ 
channels. In particular, glutamate and NMDA recep-
tors play an important role in hippocampal functional 
changes and synaptic plasticity, including synapse for-
mation in CA1 region (Wooley et al., 1997; McEwen, 
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2001), regulation of adult neurogenesis of dentate 
gyrus granule cells (Cameron et al., 1995; Gould & 
Tanapat, 1999) or remodeling of apical dendrites in 
CA3 area (McEwen, 2001). Increasing evidence sug-
gests that alterations in the glutamatergic system and 
particularly in the NMDA receptor function likely 
contribute to deficiencies in hippocampal synaptic 
plasticity and, thereby, cell loss and/or atrophy that 
will lead to morphometric changes demonstrated in 
patients with severe, recurrent and chronic mood 
disorders (Sapolsky, 2000; Maeng & Zarate, 2007).
hIppocampal glutamatergIc 
neurotransmIssIon – relevance  
to mood dIsorders 
Recent brain imaging studies and complementary 
postmortem investigations in patients with severe, 
prolonged mood disorders have found structural, 
morphometric changes, indicative of either neuro-
nal or glial cell loss and or/atrophy, preeminently in 
the hippocampal formation, but also in the amyg-
dala, prefrontal cortical regions and anatomically 
related parts of the striatum and thalamus (Manji et 
al., 2003; Sapolsky, 2000). For example, volumetric 
MRI studies from patients with MDD found about 
10% to 20% reduction in left hippocampal volume, 
and roughly 10% reduction in right hippocampal 
volume, and there was a correlation between hippo-
campal atrophy and total lifetime duration of depres-
sion. Additionally, large hippocampal low signal foci 
also correlated with cumulative depression duration, 
hinting that repeated stress associated with recur-
rent depressive states leads to hippocampal injury as 
reflected in volume loss and/or lesions. One of the 
most consistent findings of brain imaging studies in 
MDD is the affected left hippocampus either unilat-
erally (Bremner et al., 2000; Mervaala et al., 2000) 
or in the context of bilateral hippocampal volume 
reduction (Sheline et al., 1996, 1999). Another MRI 
study reported no significant hippocampal atrophy 
in patients afflicted with MDD compared to control 
subjects, but a negative correlation was established 
between the left hippocampal volume in men and 
the severity of depression determined by Hamilton 
Depression Rating Scale baseline values (Vakili et 
al., 2000). Interestingly, responder women showed 
significantly higher right hippocampal volume than 
nonresponders in this study providing further sup-
port to a conceivable association between structural 
substrates and biochemical (hormonal) states as well 
as the severity of disorder, including resistance to 
treatment. In addition, there are data indicating cor-
relation between reduction in left hippocampal grey 
matter density and impairment of verbal performance 
in treatment-resistant chronic depression (Shah et al., 
1998). These results suggest that hippocampal atrophy 
is a consequence of depression and atrophy will lead 
to cognitive deficits. Nevertheless, reversed causality 
seems to be plausible at least in a subpopulation of pa-
tients, raising the issue that (cognitive) consequences 
of a small hippocampus could predispose toward 
depression. It was found, for example, that pediatric 
patients with familial MDD displayed bilaterally re-
duced hippocampal volume, which may be suggestive 
of a causative factor for developing MDD (MacMaster 
et al., 2008). The possible mechanisms which might 
lead to hippocampal atrophy as well as reduced vol-
umes in other limbic and also prefrontal and frontal 
cortical structures in severe mood disorders (Sheline 
et al., 1998; Lai et al., 2000; Bremner et al., 2002) 
include impairments of structural plasticity such as 
inhibition of neurogenesis, regression of dendritic 
processes and loss of neurons, likely by an NMDA-
receptor mediated glutamatergic pathomechanism 
(Sapolsky, 2000; McEwen, 2001). In this context, it is 
noteworthy that prominent reductions in glial cells 
in the related brain regions, mainly in the amygdala, 
medial and orbital prefrontal cortex, could be of par-
ticular interest in view of the glial functions. Indeed, 
there is a growing awareness that glia play crucial roles 
in the regulation of synaptic glutamate concentrations 
as well as in releasing neurotrophic factors involved 
in the development and maintenance of synaptic plas-
ticity (Coyle & Schwarcz, 2000; Ullian et al., 2001). 
Thus, reduced glia and/or glial dysfunction can be 
interpreted as consistent and integral phenomena of 
the glutamate-mediated pathophysiology and altered 
synaptic plasticity in mood disorders.             
Considering the presumed pathogenesis of mood 
disorders leading to changes in synaptic plasticity, 
impairments of cellular morphology and function-
ing in response to various stressors have received 
substantial attention in recent investigations. There is 
considerable evidence that severe stressful conditions 
as well as high glucocorticoid (GC) levels influence 
cellular morphology, resulting in neuronal atrophy 
and death in the hippocampus and related limbic 
regions. Consistent with either neuroimaging or post-
mortem studies in mood disorders demonstrating 
atrophy in these areas, stress and stress-induced 
hippocampal changes have therefore been in the focus 
of neurobiological studies. Moreover, stress has largely 
been proved to significantly enhance the risk for the 
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onset of mood disorders in individuals predisposed, 
however, by a genetic vulnerability as mood disorders 
have definitely a marked genetic background. These 
appreciations fully support the contention that stress 
is an influential element in mood disorders. Stress, 
actually considered as the major precipitating fac-
tor of depression and depression are often associ-
ated with elevated GC levels. Stress and GCs have 
been shown to cause atrophy and death of the CA3 
pyramidal neurons and to decrease neurogenesis of 
dentate granule cells, these adverse effects being pre-
eminently mediated by increased glutamate release, 
through an NMDA-receptor mediated excitatory 
pathway, and by decreased expression of the brain-
derived neurotrophic factor (BDNF) (Duman et al., 
1999). Accordingly, blockade of NMDA receptors 
enhance granule cell proliferation, whereas activa-
tion of NMDA receptors inhibits this process (Gould 
& Tanapat, 1999). Conversely to the stress-induced 
decrease of neurogenesis, serotonin (5-HT) stimu-
lates granule cell proliferation, at least in part, via 
up-regulation of BDNF. Therapeutic interventions 
Figure 1 Interactions of glutamate via NMDA receptors with distinct mechanisms of normal and pathological brain functioning with focus 
on the hippocampus, presumed to be relevant to depression. Arrows show involvement of glutamate/NMDA receptors and glia in promi-
nent CNS processes, thick arrows indicate stimulation/facilitation, whereas striped arrows denote inhibitory effects. BDNF: brain-derived 
neurotrophic factor, bFGF: basic fibroblast growth factor, CA: Cornu Ammonis, DG: dentate gyrus, 5-HT: 5-hydroxytryptamine (serotonin), 
LTP: long-term potentiation, NMDA: N-methyl-d-aspartate.
Neuropsychopharmacologia huNgarica 2012. XiV. éVf. 1. szám 34
revIew  Réka Szakács, Zoltán Janka and János Kálmán
that increase serotonergic neurotransmission (antide-
pressants) may prevent the down-regulation of BDNF 
and augment neurogenesis and consequently block 
or reverse hippocampal atrophy (Figure 1). 
Given the potential role of glutamate, and particu-
larly, the role of NMDA receptors in neuroplasticity 
deficiency that may lie behind the pathophysiology of 
mood disorders, it is of great interest to assess novel 
treatment strategies in order to reduce glutamate-
mediated impairments and to modulate glutamatergic 
neurotransmission.  
The glutamatergic system, and predominantly the 
different antiglutamatergic agents that modulate dif-
ferent parts of this system have, therefore, received 
great attention in an effort to diminish glutamate-
mediated excitotoxicity and to better regulate gluta-
mate levels in these disorders. Various glutamatergic 
modulators, including antagonists of glutamate recep-
tors proved to exert important neuroprotective effects 
in several preclinical paradigms and methodological 
issues as well as in humans afflicted with these dis-
orders. The neuroprotective properties of glutamate 
receptor antagonist drugs might be of rising interest 
also in severe, recurrent, chronic mood disorders, 
particularly since structural brain imaging studies 
have revealed morphometric alterations in mood 
disturbances denotative of cell damage and/or loss. 
Thus, different antagonists of the NMDA subtype of 
the ionotropic glutamate receptors as well as other 
modulators of the glutamatergic system have already 
been evaluated and are currently being investigated 
for therapeutic purposes in depression. Existing pre-
clinical and clinical data suggest that NMDA receptor 
antagonists, apart from and/or in association with 
their neuroprotective effects, have notable antidepres-
sant properties.
the nmda receptor as a therapeutIc 
target   
The glutamatergic synaptic connections are based 
upon the concerted action of α-amino-3-hydroxy-5-
methyl-4-isoxazole propionate (AMPA), N-methyl-d-
aspartate (NMDA), and kainate (KA) type ionotropic 
glutamate receptors as well as G-protein-coupled 
metabotropic receptors. The ionotropic glutamate 
receptors are ligand-gated ion channels, named for 
the agonists that selectively activate them: NMDA, 
AMPA and KA, the latter two groups often referred 
to together as non-NMDA receptors (Wenthold & 
Roche, 1998; Molnar & Isaac, 2002). NMDA and 
AMPA receptors are co-localized in about 70% of 
adult excitatory synapses and are densely expressed 
in the cerebral cortex, hippocampal formation, amy-
gdala, striatum and septum (Bekkers & Stevens, 1989). 
AMPA receptors are stimulated directly by the pres-
ence of glutamate, and their activation opens the 
channel allowing the inflow of Na+ ions resulting in 
fast depolarization of the postsynaptic neuron. Un-
like AMPA receptors, activation of NMDA receptors 
requires the binding of glutamate and the presence 
of the coagonist glycine or D-serine, as well as depo-
larization of the membrane to liberate Mg2+ from the 
NMDA receptor channel. The NMDA receptor pore is 
blocked by Mg2+ ion in a voltage-dependent manner 
and only activation of AMPA receptors at the same 
synapse, resulting in membrane depolarization can 
relieve the voltage-dependent Mg2+ block, permitting 
the inflow of Na+ and Ca2+ ions through the pore. It 
has been argued, thereby, that AMPA receptors are 
implicated in rapid, moment-to-moment neuronal 
information transfer, whereas NMDA receptors act 
primarily as detectors of specific activity patterns 
that lead to long-term synaptic changes (Molnar & 
Isaac, 2002). 
Under a variety of pathological conditions (e.g. 
hypoxia, neurodegenerative disorders) the concentra-
tion of glutamate in the synaptic spaces excessively 
increases leading to activation of glutamate recep-
tors and finally to massive, uncontrolled Ca2+ influx 
via NMDA receptor channels which is thought to 
be responsible for excitotoxicity. NMDA receptors, 
therefore, play a key role in the integration of intra- 
and extracellular signalling.       
The NMDA receptor channel complex consists 
of the combination of NR1, NR2 (NR2A-NR2D) 
and NR3 (NR3A and NR3B) subunits. Glutamate’s 
binding site is localized to the NR2 subunit and the 
site for the coagonist glycine has been found in the 
NR1 subunit. It is noteworthy that the polyamine 
site is also localized to NR1/NR2B and compounds 
acting on polyamine site can modulate NMDA me-
diated responses. Inside the ion channel, it has been 
identified the “s” site and the phencyclidine (PCP) 
binding site, and the latter is the binding site also for 
ketamine and dizocilpine (MK-801). As mentioned, 
Mg2+ permanently blocks the receptor channel when 
the membrane is in the resting state. 
Competitive NMDA antagonists 
2-amino-5-phosphonovaleric acid (AP5) and 2-ami-
no-7-phophonoheptanoic acid (AP7) were identified 
as competitive, selective NMDA antagonists, followed 
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by a series of other competitive NMDA antagonists, 
such as d-CPP and d-CPPene. Competitive NMDA 
antagonists as modulators of the glutamatergic system 
are experimental drugs used in preclinical studies 
and their toxicity and/or side effects strongly limit 
the possible clinical utility. Nevertheless, preclinical 
investigations with competitive NMDA antagonists 
provided further evidence for glutamate’s involve-
ment in the mechanism of antidepressant action. For 
example, AP-7 (among other NMDA antagonists) 
has been shown to imitate the effects of clinically ef-
fective antidepressants in inescapable stress models 
in rats (Trullas & Skolnick, 1990). Another study 
found that intrahippocampal administration of AP-7 
had antidepressant-like properties in forced swim 
test in rats (Padovan & Guimarães, 2004), indicating 
that NMDA-antagonism in the hippocampus has 
stress-attenuating effect. This suggests that NMDA 
receptors located in the hippocampus are involved 
in behavioural changes emerging from exposure to 
uncontrollable stressors, these behavioural changes 
being related to depressive states in humans. 
Glycine site partial antagonists: cycloserine
d-cycloserine is a broad spectrum antibiotic that acts 
at the glycine site of the NMDA receptor as partial 
agonist. At low doses d-cycloserine behaves as an 
agonist, whilst at high doses it has antagonist prop-
erties. Preclinical studies with cycloserine found 
antidepressant-like effects in animal models of de-
pression (Papp & Moryl, 1996; Lopes et al., 1997). 
Clinical studies heretofore failed to show that this 
partial antagonist of the NMDA receptor has anti-
depressant effects in MDD, although it was formerly 
registered that d-cycloserine (500–1000 mg/day dose) 
had mood elevating effects in tuberculosis patients 
(Crane, 1959, 1961). A recent controlled study of 
d-cycloserine for treatment-resistant MDD did not 
find it effective as adjuvant therapy, although the  
drug was well-tolerated and resulted in symptom 
reduction (Heresco-Levy et al., 2006). However, it 
has to be considered that the 250 mg/day dose of 
d-cycloserine employed in this study was probably 
too low.   
Channel site antagonists: high-affinity  
non-competitive NMDA receptor blockers
  
Phencyclidine (PCP), ketamine and dizocilpine as 
channel site antagonists are high-affinity non-com-
petitive NMDA receptor blockers and proved to have 
neuroprotective properties against anoxia and sei-
zure-related brain damage (Szakács et al., 2003). The 
experimental drug dizocilpine (MK-801) was found 
to have antidepressant properties in preclinical inves-
tigations, either alone or in combination with tradi-
tional antidepressants of different classes (Maj et al., 
1996; Papp & Moryl, 1993; Redmond et al., 1997; Ber-
man et al., 2000). It is of interest that chronic admin-
istration of dizocilpine displays antidepressant-like 
activity in an animal model of depression, but unlike 
conventional antidepressants, it does not restore the 
5-HT and NA neurotransmitter deficits (Redmond et 
al., 1997), suggesting that the mechanism of antide-
pressant action of NMDA-antagonism involves other 
signalling pathways and steps. Ketamine, a derivative 
of the hallucinogenic drug phencyclidine, clinically 
used for procedural sedation in emergency medicine 
and for the induction and maintenance of general 
anaesthesia, demonstrated also notable antidepres-
sant activity. Thus, administration of ketamine has 
been shown to exert antidepressant effects in animal 
models of depression, as well as in humans. Berman 
et al. (2000) reported that depressed patients experi-
enced significant, rapid (within 72 hours) and rela-
tively sustained improvement in depressive symptoms 
following ketamine treatment. Similarly, it was shown 
in a recent study (Zarate et al., 2006) that a single in-
travenous, subanaesthetic dose of ketamine (0.5 mg/
kg) resulted in robust, prompt (within 2 hours), main-
tained antidepressant effect in treatment-resistant 
MDD patients. However, treatment with ketamine 
was associated with side effects, such as dissociation, 
perceptual disturbances, transient cognitive deficits, 
euphoria, increased blood pressure and increased 
libido (Berman et al., 2000; Zarate et al., 2006). The 
psychotomimetic and euphoric properties of keta-
mine, therefore, strongly limit its clinical utility.
Low-affinity non-competitive NMDA receptor 
antagonists
Alike high-affinity open-channel blockers, low-
affinity non-competitive NMDA antagonists such 
as amantadine (1-aminoadamantane), memantine 
(1-amino-3,5-dimethyladamantane), dextrometor-
phan ((+)-3-methoxy-N-methylmorphinan) display 
anticonvulsant and neuroprotective activities (re-
viewed in Heresco-Levy et al., 2006). Some preclinical 
and clinical investigations suggest that amantadine 
and its derivative memantine might have antidepres-
sant properties. Amantadine, a well-tolerated NMDA 
antagonist, clinically is used as an antiparkinsonian 
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drug due to its dopaminergic properties and it is 
also applied as an antiviral agent in the treatment 
and prophylaxis of influenza infection. At high doses, 
amantadine decreases NMDA receptor function by 
approximately 50%, an effect attributed to the in-
stability of the drug in the NMDA receptor channel 
(Parsons et al., 1996; Danysz et al., 1997). Amantadine 
has been shown to exert antidepressant action in pa-
tients with Parkinson’s disease as well as in depressed 
patients (reviewed in Zarate et al., 2002). It is note-
worthy, that the prevalence of comorbid depression in 
Parkinson’s disease is substantial, approximates 40% 
(Reijnders et al., 2008). The antidepressant proper-
ties of amantadine in Parkinson’s disease, however, 
are supposed to be related to NMDA antagonism, 
rather than to its dopaminergic effects. Furthermore, 
apart from NMDA antagonism and dopaminergic 
properties, amantadine acts through some other 
mechanisms as it has serotonergic and noradrenergic 
activity, blocks monoamine oxidase A and appears 
to increase beta endorphin levels (reviewed in Huber 
et al., 1999). A novel aspect of amantadine’s action 
is the antiviral effect on neurotropic Borna disease 
virus (BDV), which virus is suspected to be associ-
ated with certain forms of depression. Accordingly, 
amantadine proved to have notable antidepressive 
efficacy in BDV-infected depressive patients, this ef-
fect likely being related to its antiviral property against 
BDV, a potential etiopathogenetic factor of depressive 
disorders (Dietrich et al., 2000). These multiple phar-
macological effects and modes of action, including 
that of the NMDA antagonism, could constitute the 
base of antidepressant activity. Preclinical and clinical 
studies point to antidepressant properties of amanta-
dine, but heretofore only a limited body of evidence is 
available and further investigations are necessary to 
support the possible efficacy of amantadine in MDD.
Memantine, a dimethyl derivative of amantadine, 
is a clinically well-tolerated non-competitive low-
affinity NMDA receptor blocker that easily crosses 
the blood-brain barrier (Parsons et al., 1999). Me-
mantine has been applied over decades as a treatment 
for Parkinson’s disease and spasticity with minimal 
side effects and is currently used in the treatment of 
Alzheimer’s dementia since it has been shown to im-
prove cognitive function (Reisberg et al., 2003; Kovács, 
2009). It is also being explored as possible treatment 
for a variety of indications that are supposed to be 
I. competitive nmda antagonists
                      2-amino-5-phosphonovaleric acid (AP5)
                       2-amino-7-phophonoheptanoic acid (AP7)
II. glycine site partial antagonists
           d-cycloserine
III. high-affinity non-competitive nmda receptor blockers
                      Phencyclidine (PCP)
                     Ketamine
                     Dizocilpine (MK-801)
Iv. low-affinity non-competitive nmda receptor antagonists
                    Amantadine (1-aminoadamantane)
                    Memantine (1-amino-3,5-dimethyladamantane)
                    Dextrometorphan ((+)-3-methoxy-N-methylmorphinan)
Table 1  Related NMDA antagonists acting at different sites of the receptor channel complex, supporting the involvement of glutamate 
in the mechanisms of antidepressant action as well as their potential therapeutic effects
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related to/results of glutamatergic dysfunction such 
as different types of dementia, Parkinson’s disease, 
multiple sclerosis, spasticity, tinnitus, neuropathic 
and chronic pain, epilepsy, alcohol dependency, drug 
addiction, head trauma. Considering the role of gluta-
matergic dysfunction in depression, as well as the 
favourable pharmacological profile, the tolerability 
and safety of memantine, this NMDA antagonist 
can be a novel and attractive candidate for the treat-
ment of depression. Moreover, preliminary clinical 
observations report promising antimanic and mood-
stabilizing effects of memantine also in treatment-
resistant bipolar disorder, presumably via blockade of 
NMDA-receptor mediated phenomenon of the sensi-
tization of dopamine D2 receptors (Koukopoulos et al, 
2010). Preclinical investigations have described that 
memantine possesses antidepressant-like properties 
in animal models of depression. In the forced swim 
test, memantine (and also amantadine) produced 
antidepressant-like activity as it decreased immobility 
time (Moryl & Danysz, 1993). A synergistic (hyper-
additive) antidepressant-like effect was observed 
when imipramine and fluoxetine were administered 
in combination with memantine in the forced swim 
test. Interestingly, fluoxetine, which was inactive when 
given alone, displayed a positive effect when coadmin-
istered with aminoadamantanes, such as amantadine 
and memantine, suggesting that the combination of 
traditional antidepressants and NMDA antagonists 
may produce enhanced antidepressant effect (Rogóz 
et al., 2002). This assumption could be of particular 
relevance for treatment-resistant depressive patients. 
A recent double-blind, placebo-controlled clinical 
trial of memantine found no significant antidepres-
sant effect in subjects with MDD (Zarate et al., 2006), 
although it is possible that higher doses of meman-
tine or combination of memantine with traditional 
antidepressants may be effective in the treatment of 
depression. 
concludIng remarks
Preclinical and clinical investigations of the gluta-
matergic neurotransmission recently provide fur-
ther insight into the etiology and pathophysiology 
of mood disorders. Thereby, the therapies that spe-
cifically affect and modulate this system, and par-
ticularly N-methyl-d-aspartate receptor-modulating 
agents (Table 1) hold considerable promise for the 
development of new, improved antidepressants to 
treat severe, recurrent and either refractory mood 
disorders. Might a subpopulation of patients afflicted 
with severe and difficult-to-treat mood disturbances 
respond better and/or preferentially to glutamatergic 
agents? Can NMDA receptor modulators enhance 
and/or accelerate antidepressive effects of currently 
available traditional antidepressant drugs? Further 
and continuing research is indispensable to explore 
the detailed involvement of the glutamatergic system 
in mood disorders and to open new perspectives in 
drug development.           
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A széleskörű és folyamatosan bővülő antidepresszívum „fegyvertár”, valamint a depresszió 
intenzív kutatása ellenére a súlyos, rekurrens hangulatzavarok, illetve az antidepresszívum-
rezisztens hangulatbetegségek kezelése nem kellőképpen megoldott. Jelen összefoglalóban 
megkísérelünk áttekintést nyújtani azon eredményekről, melyek alátámasztják a glutamáterg 
neurotranszmisszió súlyos hangulatzavarokban feltételezett szerepét, és ezáltal olyan terápiás 
lehetőségek számára nyitnak utat, melyek a glutamáterg rendszer normális működésének 
helyreállítását célozzák, mindenekelőtt az N-metil-d-aszpartát (NMDA) receptorok révén. 
A hangsúlyt tehát az egyik legígéretesebb terápiás lehetőségre, az NMDA-receptorok modu-
látoraira helyezzük, beleértve a kompetitív NMDA-antagonistákat, a glicin kötőhely parciális 
antagonistáit és az ioncsatorna blokkolókat: a nagy és kis affinitású nem kompetitív NMDA-
receptor antagonistákat. A glutamáterg rendszert specifikusan moduláló terápiák, főként 
a kis affinitású nem kompetitív NMDA-antagonisták, így az amantadin, vagy annak szár-
mazéka, a memantin, melyek klinikailag jól tolerálható, más kórképekben és indikációkban 
már alkalmazott készítmények, igen ígéretesnek tűnnek a súlyos, rekurrens, illetve refrakter 
hangulatzavarok kezelésében, mint új típusú és hatékony(abb) antidepresszívumok. 
kulcsszavak: hangulatzavarok, depresszió, glutamáterg neurotranszmisszió, NMDA-
antagonisták, antidepresszívum
A glutamáterg neurotranszmisszió „szomorú” vetülete:  
az NMDA-receptor antagonisták mint új terápiás lehetőségek  
a major depresszió kezelésében
